English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Juvenile myoclonic epilepsy (JME) is one of the most representative idiopathic generalized epilepsies occurring in adolescence. Although epileptic seizures in JME are easily controlled by appropriate antiepileptic drug (AED) treatment, there have recently been several reports that approximately 15-20% of patients with JME are resistant to such treatment, despite an accurate diagnosis and choice of AEDs. In this study, we sought to identify risk factors that may lead to treatment resistance in patients with JME.

Clinical factors related to treatment resistance in juvenile myoclonic epilepsy